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ABSTRACT 
Objective: In this study, a RP-HPLC (stability-indicating) based assay method for the estimation of doravirine (DRV), tenofovir disoproxil fumarate 
(TFF) and lamivudine (LMV) simultaneously in the tablets was described.  
Methods: The simultaneous analysis of DRV, TFF and LMV was done with HPLC system (Agilent 1100 series) and Luna P
Results: The calibration curves were linear through the range of 25-200 
henomenex C18 (250 mm 
× 4.6 mm × 5 μ) column with isocratic mobile phase (35% volume ratio of methanol and 65% volume ratio of 20  mmol ammonium formate, pH 5). 
Validation of assay method was done on sensitivity, linearity, accuracy, selectivity, precision, robustness and specificity.  
µg/ml for DRV and 75-600 µg/ml for 
Conclusion: The results have allowed the method to be implemented in the tablets to quantify DRV, TFF, and LMV. 
TFF and LMV. The percent relative 
standard deviation for intraday variation/precision, interday variation/precision, intermediate precision/ruggedness and robustness were lower 
than 2%. The recovery of LMV (99.09-99.76%), TFF (99.10-99.41%) and DRV (98.65-99.28%) confirmed the good accuracy. The stability of LMV, 
TFF and DRV in 0.1N NaOH, 3% peroxide, 0.1 N HCl, UV light and dry heat of 60 °C was determined.  
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INTRODUCTION 
The human immunodeficiency virus is categorized in the Lentivirus 
genus, Retroviridae family and Orthoretrovirinae subfamily [1]. The 
human immunodeficiency virus is categorized into two groups, HIV 
type 1 and HIV type 2, based on genetic features and variations in 
the viral antigens [2]. Worldwide, the assessed number of people 
active with HIV infection as of 2019 is 38 million [3, 4]. Among 38 
million, 1.8 million were children below 15 y age and 36.2 million 
were adults. As of 2019 end, there had been global access to 
antiretroviral treatment for 25.4 million individuals with HIV 
infection. This means that still 12.6 million people are waiting. 
Delstrigo tablets, which was approved by FDA in 2018, were suggested 
as a full medication regimen for HIV type 1 infection in adults with no 
previous history of antiretroviral therapy [5, 6]. Delstrigo tablet 
contains fixed dose of doravirine (DRV-100 mg), tenofovir disoproxil 
fumarate (TFF-300 mg) and lamivudine (LMV-300 mg) [7]. DRV is a 
non-nucleoside analogue while TFF and LMV are nucleoside 
analogues. These three drugs (DRV, TFF and LMV) act as an inhibitor 
for reverse transcriptase enzyme in HIV, causes viral DNA chain 
termination that leads to the inhibition of viral replication [8-13].  
To quantify LMV, spectrophotometry [14, 15] and HPLC [16-19] 
based methods were proposed. TFF was quantified using 
spectrophotometry [20], HPLC [21-24] and LC-MS [25, 26] based 
methods. To determine DRV, LC-MS [27] based method was 
proposed. There is still no method for estimating the combination of 
DRV, TFF and LMV in tablets. The combination of DRV, TFF and LMV 
is not endorsed in any Pharmacopeia. It is therefore prerequisite to 
develop a simple quantitative method for estimating the 
combination of DRV, TFF and LMV in tablets. Current work describes 
a specific RP-HPLC (stability-indicating) method for estimating the 
content of DRV, TFF and LMV simultaneously in tablets. 
MATERIALS AND METHODS 
Instrument 
The simultaneous analysis of DRV, TFF and LMV in the tablets and 
bulk materials was done with the HPLC system (Agilent 1100 series, 
G1311 A Quaternary pump, G1316 A thermostat column, G1329 A 
autosampler and programmable G1314 A UV detector) and Luna 
P
Chemicals 
henomenex C18 (250 mm × 4.6 mm × 5 μ). 
DRV, TFF and LMV reference samples were collected from Merck 
Pharmaceutical Ltd (Mumbai), Cipla Ltd (Hyderabad) and Aurobindo 
Pharma Ltd (Hyderabad), respectively. Delstrigo tablets (Merck and 
Co., Inc., NJ, USA) claimed to have 100 mg of DRV, 300 mg of TFF and 
300 mg of LMV were procured locally. Methanol (HPLC class, Merck, 
Mumbai), ammonium formate (AR grade, Qualigens Fine Chemicals 
Ltd. Maharashtra), formic acid (AR grade, Qualigens Fine Chemicals 
Ltd. Maharashtra), water (HPLC class
HPLC conditions 
, Milli-Q, Merck), hydrochloric 
acid (AR grade, Rankem Chemicals Ltd, Maharashtra), sodium 
hydroxide (AR grade, Rankem Chemicals Ltd, Maharashtra) and 
peroxide (AR grade, Rankem Chemicals Ltd, Maharashtra) were used.  
Separation and assay of DRV, TFF, LMV and their forced degraded 
products were achieved on the Luna Phenomenex C18 (250 mm × 4.6 
mm × 5 μ). The mixture of methanol (35% volume ratio) and 20 mmol 
ammonium formate (65% volume ratio, pH 5.0 set with 0.1% formic 
acid) was opted as mobile phase. The elution was operated in an 
isocratic system with 1 ml/min flow rate of opted mobile phase and 20 
μl of sample injection volume. The temperature at the column was 
ambient. The detection and quantification of 
DRV, TFF, LMV combination solutions 
DRV, TFF, LMV were done 
with the UV detector tuned at 234 nm. Methanol (50% volume ratio) 
and water (45% volume ratio) was employed as the solvent system 
(diluent) for preparing sample and standard solutions.  
Standard stock combination solution (DRV-1000 µg/ml, TFF-3000 
µg/ml, LMV-3000 µg/ml) was made ready by dissolving accurate 
quantities of DRV (100 mg), LMV (300 mg) and TFF (300 mg) in 30 
ml of the diluent solvent system followed by dilution with the opted 
mobile phase to 100 ml.  
10 ml of the above standard stock combination solution was further 
diluted to 100 ml with opted mobile phase to get working 
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combination solution with concentration 100 µg/ml of DRV, 300 
µg/ml of TFF and 300 µg/ml 
Calibration curves of DRV, TFF and LMV 
of LMV.  
Standard stock combination solution (DRV-1000 µg/ml, TFF-3000 
µg/ml, LMV-3000 µg/ml) was diluted serially with the opted mobile 
phase to obtain seven solutions. The concentrations of DRV, TFF and 
LMV in seven solutions were:  
Solution 1: DRV-25 µg/ml, TFF-75 µg/ml, LMV-75 µg/ml 
Solution 2: DRV-50 µg/ml, TFF-150 µg/ml, LMV-150 µg/ml 
Solution 3: DRV-75 µg/ml, TFF-225 µg/ml, LMV-225 µg/ml 
Solution 4: DRV-100 µg/ml, TFF-300 µg/ml, LMV-300 µg/ml 
Solution 5: DRV-125 µg/ml, TFF-375 µg/ml, LMV-375 µg/ml 
Solution 6: DRV-150 µg/ml, TFF-450 µg/ml, LMV-450 µg/ml 
20 µl of each solution was applied to 
Solution 7: DRV-200 µg/ml, TFF-600 µg/ml, LMV-600 µg/ml 
the HPLC system and analysed 
through employing the proposed methodology. The peak areas of 
DRV, TFF and LMV at every concentration were recorded. The 
calibration curves were charted in the range of 25-200 µg/ml for 
DRV and 75-600 µg/ml for 
Estimation of DRV, TFF and LMV in tablets 
TFF and LMV. 
Weight of ten tablets (each having 100 mg of DRV, 300 mg of TFF 
and 300 mg of LMV) was measured and crushed to powder. A 
powder weight equal to 100 mg of DRV, 300 mg of TFF and 300 mg 
of LMV was dissolved in diluent solvent system by sonication for 20 
min. After sonication, the resulting solution was and diluted to a 
volume of 100 ml with opted mobile phase system. 10 ml of the 
above stock tablet solution was further diluted to 100 ml with opted 
mobile phase to get working tablet solution for assay. 20 µl samples 
of working tablet solution 
Degradation studies  
were applied to the HPLC system. 
Applying the proposed methodology, chromatograms and peak 
areas for DRV, TFF, and LMV were recorded. The quantities of DRV, 
TFF, and LMV present in tablets were obtained from DRV, TFF, and 
LMV calibration curves or their regression equations, respectively. 
Degradation study was conducted on the
Hydrolytic degradation with 0.1N HCl 
 tablet solution using 0.1N 
NaOH, 3% peroxide, 0.1 N HCl and on tablet powder using UV light 
and Dry heat of 60 °C [28]. 
10 ml of stock tablet solution (DRV-1000 µg/ml, TFF-3000 µg/ml, 
LMV-3000 µg/ml) was left for 24 h with 50 ml of 0.1N HCl solution 
at room temperature. The solution was then neutralized using 0.1N 
NaOH solution, filtered and the volume was diluted to 100 ml with 
opted mobile phase system. 20 µl samples of 0.1N HCl degraded 
tablet solution 
Hydrolytic degradation with 0.1N NaOH 
were applied to the HPLC system and analysed by 
applying the proposed methodology. It was determined how much 
quantities of DRV, TFF, and LMV remained in tablets. 
10 ml of stock tablet solution (DRV-1000 µg/ml, TFF-3000 µg/ml, 
LMV-3000 µg/ml
Oxidative degradation with 3% peroxide 
) remained at room temperature for 24 h with 50 
ml of 0.1N NaOH solution. The solution was then neutralized using 
0.1N HCl solution, filtered and the volume was diluted to 100 ml 
with opted mobile phase system. 20 μl sample of 0.1N NaOH 
degraded tablet solution was added to the HPLC device and analysed 
using the suggested methodology. The quantities of DRV, TFF, and 
LMV remained in tablets were determined. 
10 ml of stock tablet solution (DRV-1000 µg/ml, TFF-3000 µg/ml, 
LMV-3000 µg/ml
Thermal degradation at 60 °C 
) was mixed with 50 ml of 3% peroxide for 24 h, 
filtered, and completed to 100 ml volume with opted mobile phase 
system. 20 μl sample of peroxide degraded tablet solution was 
added to the HPLC device, analysed using the methodology 
suggested. The quantities of DRV, TFF, and LMV remained in tablets 
were determined. 
The tablet powder weight equal to 100 mg of 
Photodegradation using UV light (254 nm) 
DRV, 300 mg of TFF 
and 300 mg of LMV was taken in petridish and placed in oven for 6 h 
at 60 °C. Upon 6 h the thermal degraded tablet sample was treated 
as described in the section "Estimation of DRV, TFF and LMV in 
tablets” to determine the quantities of DRV, TFF and LMV remained. 
The tablet powder weight equal to 100 mg of 
RESULTS 
DRV, 300 mg of TFF 
and 300 mg of LMV was taken in petridish and placed in UV chamber 
for 6 h at 254 nm. Upon 6 h the photo degraded tablet sample was 
treated as described in the section "Estimation of DRV, TFF and LMV 
in tablets” to assess the amounts of DRV, TFF and LMV remained. 
Validation 
The quantitative approach developed for the combined assay of 
DRV, TFF and LMV in the
System suitability 
 tablets has been validated in accordance 
with the standards of the International Conference on 
Harmonization [29, 30]. 
The values of tailing factor, peak areas, theoretical plates and 
resolution for DRV, TFF and LMV peaks obtained with the
  
 optimized 
assay conditions were displayed in table 1 and a typical chromatogram 
of DRV, TFF and LMV combination was furnished in fig. 1. 
Table 1: System suitability values for DRV, TFF and LMV obtained with optimized assay conditions 
Parameter Results RSD* ** Acceptable limit   



























Value should exceed 2000 






Value should be equal or less than 2.0 
*mean for five values; **RSD for five values 
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Fig. 1: DRV, TFF and LMV chromatogram obtained with optimized assay conditions 
 
Selectivity  
Specificity was demonstrated by assessing the chromatograms 
attained with the analysis of working combination solution (DRV-
100 µg/ml, TFF-300 µg/ml, LMV-300 µg/ml), blank diluent solvent 
system and working tablet solution (DRV-100 µg/ml, TFF-300 
µg/ml, LMV-300 µg/ml). Fig. 2 shows the representative 
chromatograms. No peaks were identified in the chromatogram (fig. 
2a) of the blank diluent solvent system. The retention times of LMV, 
TFF and DRV in the chromatogram (fig. 2c) of working tablet 
solution was confirmed with retention times of LMV, TFF and DRV in 
the chromatogram (fig. 2b) of working combination solution. 
Additional peaks other than LMV, TFF and DRV peaks were not 
identified in the chromatogram (fig. 2c) 
  
of working tablet solution. 
 
Fig. 2: Chromatograms of (a) Blank diluent solvent system (b) Working combination solution (c) Working tablet solution 
 
Linearity  
LMV, TFF, and DRV calibration curves were generated by a linear 
regression system. The range of linearity investigated was 25-200 
µg/ml for DRV and 75-600 µg/ml for TFF and LMV with coefficients 
of regression 0.9991 (LMV), 0.9989 (TFF) and 0.9998 (DRV). The 
equations obtained with linear regression system were:  
Peak response area = 1571.3 x+27624 for LMV 
Peak response area = 1795.6 x+38515 for TFF 
Peak response area = 1523.6 x–3814 for DRV 
Quantification limit and detection limit 
For this assay procedure, the quantification and detection limits 
were estimated on the basis of the standard deviation (STD) of area 
response and slope (SE) of calibration graph by using the




given here [29, 30]:  
Quantification limit = 10 × STD
SE
 
The detection limits for LMV, TFF and DRV were 1.623 µg/ml, 3.326 
µg/ml and 0.705 µg/ml, respectively. The quantification limits were 
4.918 µg/ml, 10.078 µg/ml and 2.136 µg/ml for LMV, TFF and DRV, 
respectively. The method presented was, therefore, sufficiently 
sensitive for the combined assay of LMV, TFF and DRV in tablets. 
Precision 
The precision of the assay method was determined as intraday 
variation/precision, interday variation/precision and intermediate 
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precision/ruggedness. Intraday variation/precision was 
demonstrated using six measurements of the working combination 
solution (DRV-100 µg/ml, TFF-300 µg/ml and LMV-300 µg/ml) on 
the same day. Intraday variation/precision was demonstrated by 
measurements of the working combination solution (DRV-100 
µg/ml, TFF-300 µg/ml and LMV-300 µg/ml) on 3 different days. 
Intermediate precision/ruggedness was demonstrated by 
measurements of the working combination solution (DRV-100 
µg/ml, TFF-300 µg/ml and LMV-300 µg/ml) by different analysts. All 
details are mentioned in table 2. 
  
Table 2: Repots of precision investigation 
Parameter LMV TFF DRV 
Intraday variation/precision 
Mean peak area* (n=6) 489481.37 593863.02 148831.17 
RSD of peak areas** (n=6) 0.158 0.305 0.219 
Interday variation/precision–Day 1 
Mean peak area$ 491195.50  (n=3) 594005.73 148971.97 
RSD of peak areas$$ 0.108  (n=3) 0.441 0.422 
Interday variation/precision–Day 2 
Mean peak area$ 489190.10  (n=3) 596195.33 150010.37 
RSD of peak areas$$ 0.421  (n=3) 0.719 0.892 
Interday variation/precision–Day 3 
Mean peak area$ 489338.87  (n=3) 593807.03 149069.80 
RSD of peak areas$$ 0.153  (n=3) 0.197 0.108 
Over all Interday variation/precision 
Mean peak area$
(Days 1,2,3) 
  489908.16 594669.36 149350.71 
RSD of peak areas$$
(Days 1,2,3) 
  0.228 0.223 0.384 
Intermediate precision/ruggedness–Analyst 1 
Mean peak area$ 490770.80  (n=3) 595747.07 148936.20 
RSD of peak areas$$ 0.631  (n=3) 0.196 0.792 
Intermediate precision/ruggedness–Analyst 2 
Mean peak area$ 488962.70  (n=3) 595556.70 146049.03 
RSD of peak areas$$ 0.257  (n=3) 0.286 1.082 
Over all Intermediate precision/ruggedness 
Mean peak area#
(Analysts 1 and 2) 
  489866.75 595651.89 147492.62 
RSD of peak areas##
(Analysts 1 and 2) 
  0.261 0.023 1.384 
*mean for six values; **RSD for six values; $mean for three values; $$RSD for three values; #mean for two values; ##
 
RSD for two values 
Robustness 
The robustness of the assay method was checked by making 
marginal and deliberate modifications to experimental 
parameters, for example methanol ratio and pH in the mobile 
phase solvent system, and detection wavelength. The working 
combination solution (DRV-100 µg/ml, TFF-300 µg/ml and LMV-
300 µg/ml) was analysed with changed conditions and optimized 
conditions. Analysed the working combination solution (DRV-100 
µg/ml, TFF-300 µg/ml and LMV-300 µg/ml) with modified assay 
conditions and optimized assay conditions. All details are 
mentioned in table 3. 
  
Table 3: Repots of robustness investigation 
Parameter LMV TFF DRV 
Mobile phase  
Optimal assay condition (methanol 35% vol and 20 mmol 
ammonium formate 65% vol) 
490020.3 595154.8 149673.8 
Modified assay condition 1 
(methanol 40% vol and 20 mmol ammonium formate 60% vol) 
491395.1 591246.3 148239.1 
Modified assay condition 2 
(methanol 30% vol and 20 mmol ammonium formate 70% vol) 
486267.9 590362.7 149582.6 
Mean peak area$ 489227.77  (n=3) 592254.60 149165.17 
RSD of peak areas$$ 0.542  (n=3) 0.431 0.539 
pH  
Optimal assay condition  
(pH 5.0) 
490020.3 595154.8 149673.8 
Modified assay condition 1 
(pH 4.9) 
488987.2 596316.8 150021.4 
Modified assay condition 2 
(pH 5.1) 
493636.2 589956.4 148991.1 
Mean peak area$ 490881.23  (n=3) 593809.33 149562.10 
RSD of peak areas$$ 0.497  (n=3) 0.570 0.350 
Detection wavelength  
Optimal assay condition  
(234 nm) 
490020.3 595154.8 149673.8 
Modified assay condition 1 
(229 nm) 
494591.8 597974.5 147676.9 
Modified assay condition 2 
(239 nm) 
493263.5 590467.1 148582.4 
Mean peak area$$ 492625.20  (n=3) 594532.13 148644.37 
RSD of peak areas$$ 0.477 (n=3) 0.638 0.673 
$mean for three values; $$RSD for three values 
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Accuracy 
To demonstrate accuracy, LMV, TFF and DRV spiked tablet sample 
solutions were analysed. The recovery of spiked LMV, TFF and DRV 
concentrations at different levels are given in table 4. The obtained 
recovery is in the range of 98.65-99.76% for LMV, TFF and DRV. 
Stability of LMV, TFF and DRV 
The stability of LMV, TFF and DRV in the
  
 applied degradation 
conditions like 0.1N NaOH, 3% peroxide, 0.1 N HCl, UV light and dry 
heat of 60 °C was studied through degradation studies. The percentage 
quantity of LMV, TFF and DRV degraded was shown in table 5. 
Table 4: Reports of accuracy investigation 
50% spiked accuracy 100% spiked accuracy 150% spiked accuracy 
Concentration (µg/ml) Recovery 
percent 
Concentration (µg/ml) Recovery 
percent 
Concentration (µg/ml) Recovery 
percent Spiked  Quantified  Spiked  Quantified  Spiked  Quantified  
Lamivudine accuracy reports  
150 148.14 98.76 300 297.45 99.149 450 449.10 99.8 
150 149.58 99.72 300 297.83 99.275 450 448.43 99.65 
150 149.04 99.36 300 296.57 98.857 450 449.19 99.82 
Mean$ 99.28  recovery Mean$ 99.09  recovery Mean$$ 99.76  recovery 
RSD$$ 0.488  of recovery  RSD$$ 0.216  of recovery  RSD$$ 0.093  of recovery  
Tenofovir disoproxil fumarate accuracy reports 
150 149.07 99.38 300 297.45 99.15 450 448.56 99.68 
150 148.52 99.01 300 299.08 99.69 450 442.58 98.35 
150 148.37 98.91 300 298.12 99.37 450 446.72 99.27 
Mean recovery 99.10 $ Mean$$ 99.41  recovery Mean$$ 99.10  recovery 
RSD$$ 0.250  of recovery  RSD$$ 0.274  of recovery  RSD$$ 0.687  of recovery  
Doravirine accuracy reports 
50 49.67 99.33 100 98.49 98.49 150 147.72 98.48 
50 49.64 99.28 100 99.05 99.05 150 148.38 98.92 
50 49.62 99.23 100 99.46 99.46 150 147.84 98.56 
Mean$ 99.28  recovery Mean$ 99.00  recovery Mean$ 98.65  recovery 
RSD$$ 0.050  of recovery  RSD$$ 0.492  of recovery  RSD$$ 0.238  of recovery  
$mean for three values; $$
 
RSD for three values 
Table 5: Reports of stability investigation 














0.1N HCl 5.86 94.14 0.431 6.88 93.12 0.585 6.86 93.14 0.333 
Dry heat of 60 °C 2.10 97.90 0.884 2.83 97.17 1.555 2.27 97.73 1.075 
0.1N NaOH 7.69 92.31 0.140 8.19 91.81 0.124 6.45 93.55 0.660 
3% Peroxide 6.08 93.92 1.371 5.62 94.38 0.967 5.04 94.96 0.999 
UV Light 8.92 91.08 0.162 9.31 90.69 0.104 8.14 91.86 0.628 
*mean for three percent degraded values 
 
 
Fig. 3: Chromatograms of (a) 0.1N HCl (b) 0.1N NaOH (c) 3% peroxide (d) Dry heat (e) UV light degraded tablet solution 
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Table 6: Repots of tablet analysis 
Parameter LMV TFF DRV 
Content (mg) in tablet 300 300 100 
Mean$ 298.08  quantified (mg) (n=3) 296.04 99.14 
Mean$ 99.36  assay percent (n=3) 98.68 99.14 
RSD$$ 0.118  of assay percent (n=3) 0.062 0.433 
$mean for three values; $$
 
RSD for three values 
Specificity  
The resolution of LMV, TFF, DRV and its degradation components, as 
shown in chromatograms (fig. 3a-e) of degraded tablet sample solutions, 
showed stability, indicating characteristic feature and specificity of assay 
method for the LMV, TFF and DRV combined analysis. 
Application of assay method to the tablets 
The assay method established was employed to evaluate the LMV, 
TFF, and DRV content in the Delstrigo tablets (DRV-100 mg, TFF-300 
mg and LMV-300 mg). The reports of LMV, TFF and DRV content 
evaluation in the
DISCUSSION 
 Delstrigo tablets was displayed in table 6. The 
obtained recovery (98.68-99.36%) values and RSD of percent assay 
(0.062-0.433%) values of LMV, TFF and DRV confirming the good 
accuracy and precision of the assay method for the LMV, TFF and 
DRV combined analysis in tablets. 
For quantification of LMV, TFF and DRV, methods using 
spectrophotometry [14, 15, 20], HPLC [16-19, 21-24] and LC-MS [25-
27] were found. But these methods [14-27] were used to quantify 
LMV, TFF and DRV individually in samples. These methods [14-27] 
were not applied for the combined quantification of LMV, TFF and 
DRV. Therefore, a stability-indicating HPLC methodology was 
established in this study to analyse DRV, TFF and LMV in combination. 
During development, essential parameters like the solvent 
combination as mobile phase, pH and column as stationary phase were 
examined. The column as stationary phase examined include 
Lichrospher ODS RP-18 (4.5 mm × 150 mm × 5 µm), Waters RP-18 
column having dimensions of 4.5 mm × 150 mm × 5 µm and 4.5 mm × 
250 mm × 5 µm, and Phenomenex luna C18 having dimensions of 4.5 
mm × 150 mm × 5 µm and 4.5 mm × 250 mm × 5 µm. The solvent 
combinations examined were methanol: buffer of ammonium acetate 
(0.1M, pH 5.2) in 70:30 vol/vol ratio, acetonitrile: buffer of phosphate 
(0.1M, pH 5.5) in 50:50 vol/vol ratio, methanol: buffer of phosphate 
(0.1M, pH 5.0) in 30:70 vol/vol ratio, methanol: buffer of acetate 
(0.1M, pH 5.7) in 40:60 vol/vol ratio, methanol: ammonium formate 
(20 mmol, pH 5.0, 5.8, 6.1) in ratios like 50:50 vol/vol, 70:30 vol/vol 
and 35:65 vol/vol. The flow rate remains constant all along the trails at 
1.0 ml per min. During trails, the results were checked for values of 
tailing factor, peak areas, theoretical plates and resolution for the
The method presented was selective for the combined assay of LMV, 
TFF and DRV in tablets without interruption with diluent solvent 
system components and tablet excipients [14-27,29,30]. The 
coefficients of regression higher than 0.99 indicating a lined 
correlation between the LMV, TFF, and DRV concentration and their 
respective area responses [14-27,29,30]. The method was 
sufficiently sensitive for the combined assay of LMV, TFF and DRV in 
tablets because of low values of quantification and detection limits 
[14-27,29,30]. The precision results were below 2% RSD. The 
reports indicated that the assay method was precise for the LMV, 
TFF and DRV combined analysis [14-27,29,30]. The robustness 
results were below 2% RSD. It was verified that there were no 
significant changes in the reports showing that the presented assay 
method was robust for the LMV, TFF and DRV combined analyses. 
The obtained recovery (98.65-99.76%) values of LMV, TFF and DRV 
confirming the good accuracy of assay method for the LMV, TFF and 
DRV combined analysis [14-27,29,30]. During degradation, the order 
of stability was [28]:  
 DRV, 
TFF and LMV peaks. Better, satisfactory and acceptable results were 
achieved with Luna phenomenex C18 (4.5 mm × 250 mm × 5 µm) 
stationary phase at ambient temperature with methanol: ammonium 
formate (20 mmol, pH 5.0) in ratio of 35:65 vol/vol as mobile phase. 
Better sensitivity (peak areas) for DRV, TFF and LMV was obtained 
with UV detector set at 234 nm.  
LMV: Dry heat of 60 °C ˃ 0.1N HCl ˃ 3% Peroxide ˃ 0.1N NaOH ˃ UV light 
TFF: Dry heat of 60 °C ˃ 3% Peroxide ˃ 0.1N HCl ˃ 0.1N NaOH ˃ UV light 
DRV: Dry heat of 60 °C ˃ 3% Peroxide ˃ 0.1N NaOH ˃ 0.1N HCl ˃ UV light 
CONCLUSION 
Current work described a RP-HPLC (stability-indicating) method for 
estimating DRV, TFF and LMV simultaneously. This method can be 
preferred for the quantification of DRV, TFF and LMV 
simultaneously in the
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